United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,218 shares of the firm’s stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $140.16, for a total transaction of $170,714.88. Following the transaction, the chief executive officer now directly owns 1,358 shares of the company’s stock, valued at $190,337.28. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of United Therapeutics Co. (NASDAQ:UTHR) traded down 0.40% during mid-day trading on Monday, reaching $141.51. 317,011 shares of the company traded hands. The stock has a market capitalization of $6.36 billion, a PE ratio of 9.28 and a beta of 1.42. The stock’s 50 day moving average is $155.60 and its 200 day moving average is $136.69. United Therapeutics Co. has a 52-week low of $97.52 and a 52-week high of $169.89.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.61 by $0.51. United Therapeutics had a net margin of 44.40% and a return on equity of 41.78%. The business had revenue of $409 million for the quarter, compared to analyst estimates of $415.51 million. During the same quarter in the previous year, the firm posted $3.80 earnings per share. United Therapeutics’s revenue was up 1.0% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post $14.13 earnings per share for the current year.

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Your IP Address:

Institutional investors have recently made changes to their positions in the company. Scopia Capital Management LP bought a new position in shares of United Therapeutics during the third quarter worth about $483,266,000. Norges Bank bought a new position in shares of United Therapeutics during the fourth quarter worth about $63,975,000. Russell Investments Group Ltd. bought a new position in shares of United Therapeutics during the fourth quarter worth about $61,510,000. Consonance Capital Management LP raised its position in shares of United Therapeutics by 95.5% in the third quarter. Consonance Capital Management LP now owns 818,700 shares of the biotechnology company’s stock worth $96,672,000 after buying an additional 400,000 shares during the period. Finally, First Trust Advisors LP raised its position in shares of United Therapeutics by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock worth $56,793,000 after buying an additional 231,502 shares during the period.

Several brokerages have weighed in on UTHR. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of United Therapeutics in a report on Tuesday, February 14th. Wedbush reissued an “outperform” rating and set a $229.00 price objective on shares of United Therapeutics in a report on Wednesday, February 8th. Standpoint Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 19th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Finally, Jefferies Group LLC downgraded shares of United Therapeutics from a “hold” rating to an “underperform” rating and reduced their price target for the stock from $149.47 to $116.00 in a research report on Monday, March 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $138.31.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.